ReliaTech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ReliaTech is a private, revenue-generating reagent manufacturer serving the academic and industrial research sectors. The company leverages over 25 years of collective experience in producing recombinant proteins and antibodies, positioning itself on quality, reliability, and direct customer collaboration. Its core business model is providing essential research tools (Services/Products) rather than developing therapeutics, with a specific niche in vascular biology research. While financially opaque as a private entity, its established product catalog and certification suggest a stable early-stage commercial operation.

Antibodies

Technology Platform

Established expertise in recombinant protein and antibody production, supported by ISO9001:2015 certified manufacturing processes and direct expert customer support.

Opportunities

Capitalizing on the growing demand for high-quality, reproducible research tools in vascular biology.

Leveraging the 'Made in Germany' reputation for quality to gain market share in international research markets.

Expanding the product catalog into adjacent research areas and developing animal-free or novel reagent formats.

Risk Factors

Intense competition from large, global life science reagent conglomerates with greater resources.

Dependence on the health of academic and pharmaceutical research funding cycles.

Operational risks related to bioproduction consistency and supply chain for raw materials.

Competitive Landscape

Operates in a crowded market dominated by giants like Thermo Fisher, Abcam, and Merck. Competes by offering specialized expertise in angiogenesis/lymphangiogenesis, superior customer support, and a quality-focused 'Made in Germany' production, rather than on price or catalog breadth.

More companies in Biologics / Biosimilars →More companies in Germany →